Supernus Pharmaceuticals (SUPN) Interest & Investment Income (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Interest & Investment Income of $2.6 million for Q2 2026, down 41.92% year-over-year from $4.5 million in Q2 2025, and up 1346.45% on a QoQ basis from -$211000.0 in Q1 2026.
Supernus Pharmaceuticals (SUPN) Interest & Investment Income (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Interest & Investment Income for 14 years, with the latest figure at $2.6 million in Q2 2026.
- Interest & Investment Income for Q2 2026 came in at $2.6 million, down 41.92% year-over-year; the trailing twelve-month figure through Jun 2026 was $7.0 million (up 45.99% YoY), and the FY2018 annual result was $13.8 million, up 383.34% from the prior year.
- Interest & Investment Income rose to $2.6 million in Q2 2026, from -$211000.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $4.5 million in Q2 2025 and troughed at -$211000.0 in Q1 2026.
- A 4-year average of $1.1 million and a median of $358000.0 in 2023 frame the typical range for Interest & Investment Income.
- The widest annual swing landed in 2025, when Interest & Investment Income soared 2695.06%; it then plunged 803.33% in 2026.
- A 4-year view of Interest & Investment Income shows it stood at $554000.0 in 2023, then slumped by 70.76% to $162000.0 in 2024, then soared by 2695.06% to $4.5 million in 2025, then tumbled by 41.92% to $2.6 million in 2026.
- Per Business Quant data, the three most recent Interest & Investment Income figures were $2.6 million in Q2 2026, -$211000.0 in Q1 2026, and $4.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.11 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.27 Bn | 39.61 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.81 Bn | 30.14 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.72 Bn | 22.92 Bn | 5.10 Bn | 154.39 Mn |
| 5 | United Therapeutics | 22.19 Bn | 19.53 Bn | 683.80 Mn | 31.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 12.40 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.76 Bn | 2.39 Bn | 185.39 Mn | 2.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.63 Mn |
| Mar 31, 2026 | -211,000.00 |
| Jun 30, 2025 | -41,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Jun 30, 2024 | 162,000.00 |
| Mar 31, 2024 | 59,000.00 |
| Jun 30, 2023 | 554,000.00 |
| Mar 31, 2023 | 881,000.00 |
| Sep 30, 2020 | 3.26 Mn |
| Sep 30, 2019 | 5.56 Mn |
| Jun 30, 2019 | 5.45 Mn |
| Mar 31, 2019 | 4.68 Mn |
| Dec 31, 2018 | 4.51 Mn |
| Sep 30, 2018 | 4.46 Mn |
| Jun 30, 2018 | 3.66 Mn |
| Mar 31, 2018 | 1.21 Mn |
| Dec 31, 2017 | 862,000.00 |
| Sep 30, 2017 | 814,000.00 |
| Jun 30, 2017 | 656,000.00 |
| Mar 31, 2017 | 531,000.00 |